vs
Orthofix Medical Inc.（OFIX）与PROCORE TECHNOLOGIES, INC.（PCOR）财务数据对比。点击上方公司名可切换其他公司
PROCORE TECHNOLOGIES, INC.的季度营收约是Orthofix Medical Inc.的1.6倍（$349.1M vs $219.9M），Orthofix Medical Inc.净利率更高（-1.0% vs -10.8%，领先9.8%），PROCORE TECHNOLOGIES, INC.同比增速更快（15.6% vs 2.0%），PROCORE TECHNOLOGIES, INC.自由现金流更多（$109.2M vs $16.8M），过去两年PROCORE TECHNOLOGIES, INC.的营收复合增速更高（13.8% vs 8.0%）
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
Procore Technologies是2002年成立的美国建筑管理软件即服务（SaaS）企业，总部位于加利福尼亚州卡平特里亚。公司打造的全球平台可连接建筑行业从业者，支持搭建简化工作流，统一展现建筑项目信息，覆盖任务追踪、项目流程管理、日程排期等核心功能。
OFIX vs PCOR — 直观对比
营收规模更大
PCOR
是对方的1.6倍
$219.9M
营收增速更快
PCOR
高出13.6%
2.0%
净利率更高
OFIX
高出9.8%
-10.8%
自由现金流更多
PCOR
多$92.4M
$16.8M
两年增速更快
PCOR
近两年复合增速
8.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $219.9M | $349.1M |
| 净利润 | $-2.2M | $-37.6M |
| 毛利率 | 71.1% | 80.1% |
| 营业利润率 | 0.2% | -12.3% |
| 净利率 | -1.0% | -10.8% |
| 营收同比 | 2.0% | 15.6% |
| 净利润同比 | 92.4% | 39.6% |
| 每股收益（稀释后） | $-0.05 | $-0.25 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OFIXPCOR
| Q4 25 | $219.9M | $349.1M | ||
| Q3 25 | $205.6M | $338.9M | ||
| Q2 25 | $203.1M | $323.9M | ||
| Q1 25 | $193.6M | $310.6M | ||
| Q4 24 | $215.7M | $302.0M | ||
| Q3 24 | $196.6M | $295.9M | ||
| Q2 24 | $198.6M | $284.3M | ||
| Q1 24 | $188.6M | $269.4M |
净利润OFIXPCOR
| Q4 25 | $-2.2M | $-37.6M | ||
| Q3 25 | $-22.8M | $-9.1M | ||
| Q2 25 | $-14.1M | $-21.1M | ||
| Q1 25 | $-53.1M | $-33.0M | ||
| Q4 24 | $-29.1M | $-62.3M | ||
| Q3 24 | $-27.4M | $-26.4M | ||
| Q2 24 | $-33.4M | $-6.3M | ||
| Q1 24 | $-36.0M | $-11.0M |
毛利率OFIXPCOR
| Q4 25 | 71.1% | 80.1% | ||
| Q3 25 | 72.2% | 79.7% | ||
| Q2 25 | 68.7% | 79.1% | ||
| Q1 25 | 62.8% | 79.1% | ||
| Q4 24 | 69.0% | 81.2% | ||
| Q3 24 | 68.7% | 81.4% | ||
| Q2 24 | 67.8% | 83.1% | ||
| Q1 24 | 67.5% | 83.0% |
营业利润率OFIXPCOR
| Q4 25 | 0.2% | -12.3% | ||
| Q3 25 | -8.3% | -4.4% | ||
| Q2 25 | -7.9% | -9.3% | ||
| Q1 25 | -25.2% | -11.7% | ||
| Q4 24 | -5.3% | -21.9% | ||
| Q3 24 | -9.6% | -12.3% | ||
| Q2 24 | -12.5% | -5.2% | ||
| Q1 24 | -15.6% | -7.0% |
净利率OFIXPCOR
| Q4 25 | -1.0% | -10.8% | ||
| Q3 25 | -11.1% | -2.7% | ||
| Q2 25 | -6.9% | -6.5% | ||
| Q1 25 | -27.4% | -10.6% | ||
| Q4 24 | -13.5% | -20.6% | ||
| Q3 24 | -13.9% | -8.9% | ||
| Q2 24 | -16.8% | -2.2% | ||
| Q1 24 | -19.1% | -4.1% |
每股收益（稀释后）OFIXPCOR
| Q4 25 | $-0.05 | $-0.25 | ||
| Q3 25 | $-0.57 | $-0.06 | ||
| Q2 25 | $-0.36 | $-0.14 | ||
| Q1 25 | $-1.35 | $-0.22 | ||
| Q4 24 | $-0.76 | $-0.42 | ||
| Q3 24 | $-0.71 | $-0.18 | ||
| Q2 24 | $-0.88 | $-0.04 | ||
| Q1 24 | $-0.95 | $-0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $82.0M | $768.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $450.0M | $1.3B |
| 总资产 | $850.6M | $2.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资OFIXPCOR
| Q4 25 | $82.0M | $768.5M | ||
| Q3 25 | $62.9M | $684.0M | ||
| Q2 25 | $65.6M | $620.9M | ||
| Q1 25 | $58.0M | $566.7M | ||
| Q4 24 | $83.2M | $775.4M | ||
| Q3 24 | $30.1M | $756.9M | ||
| Q2 24 | $26.4M | $735.4M | ||
| Q1 24 | $27.0M | $744.6M |
总债务OFIXPCOR
| Q4 25 | — | — | ||
| Q3 25 | $157.2M | — | ||
| Q2 25 | $157.0M | — | ||
| Q1 25 | $156.9M | — | ||
| Q4 24 | $157.0M | — | ||
| Q3 24 | $118.5M | — | ||
| Q2 24 | $118.0M | — | ||
| Q1 24 | $118.2M | — |
股东权益OFIXPCOR
| Q4 25 | $450.0M | $1.3B | ||
| Q3 25 | $442.5M | $1.2B | ||
| Q2 25 | $458.3M | $1.2B | ||
| Q1 25 | $458.3M | $1.2B | ||
| Q4 24 | $503.1M | $1.3B | ||
| Q3 24 | $525.9M | $1.3B | ||
| Q2 24 | $546.0M | $1.3B | ||
| Q1 24 | $570.3M | $1.2B |
总资产OFIXPCOR
| Q4 25 | $850.6M | $2.2B | ||
| Q3 25 | $832.6M | $2.1B | ||
| Q2 25 | $837.2M | $2.0B | ||
| Q1 25 | $823.1M | $1.9B | ||
| Q4 24 | $893.3M | $2.1B | ||
| Q3 24 | $867.9M | $2.0B | ||
| Q2 24 | $882.0M | $2.0B | ||
| Q1 24 | $906.0M | $1.9B |
负债/权益比OFIXPCOR
| Q4 25 | — | — | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.34× | — | ||
| Q1 25 | 0.34× | — | ||
| Q4 24 | 0.31× | — | ||
| Q3 24 | 0.23× | — | ||
| Q2 24 | 0.22× | — | ||
| Q1 24 | 0.21× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $27.7M | $114.9M |
| 自由现金流经营现金流 - 资本支出 | $16.8M | $109.2M |
| 自由现金流率自由现金流/营收 | 7.6% | 31.3% |
| 资本支出强度资本支出/营收 | 4.9% | 1.6% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-1.3M | $282.2M |
8季度趋势，按日历期对齐
经营现金流OFIXPCOR
| Q4 25 | $27.7M | $114.9M | ||
| Q3 25 | $12.4M | $88.5M | ||
| Q2 25 | $11.6M | $30.8M | ||
| Q1 25 | $-18.4M | $66.0M | ||
| Q4 24 | $23.7M | $29.1M | ||
| Q3 24 | $11.7M | $39.3M | ||
| Q2 24 | $9.0M | $58.7M | ||
| Q1 24 | $-18.6M | $69.1M |
自由现金流OFIXPCOR
| Q4 25 | $16.8M | $109.2M | ||
| Q3 25 | $2.5M | $83.1M | ||
| Q2 25 | $4.5M | $27.9M | ||
| Q1 25 | $-25.1M | $62.0M | ||
| Q4 24 | $15.2M | $17.4M | ||
| Q3 24 | $6.3M | $35.7M | ||
| Q2 24 | $-360.0K | $56.8M | ||
| Q1 24 | $-29.1M | $67.1M |
自由现金流率OFIXPCOR
| Q4 25 | 7.6% | 31.3% | ||
| Q3 25 | 1.2% | 24.5% | ||
| Q2 25 | 2.2% | 8.6% | ||
| Q1 25 | -13.0% | 20.0% | ||
| Q4 24 | 7.0% | 5.8% | ||
| Q3 24 | 3.2% | 12.1% | ||
| Q2 24 | -0.2% | 20.0% | ||
| Q1 24 | -15.4% | 24.9% |
资本支出强度OFIXPCOR
| Q4 25 | 4.9% | 1.6% | ||
| Q3 25 | 4.8% | 1.6% | ||
| Q2 25 | 3.5% | 0.9% | ||
| Q1 25 | 3.5% | 1.3% | ||
| Q4 24 | 4.0% | 3.9% | ||
| Q3 24 | 2.7% | 1.2% | ||
| Q2 24 | 4.7% | 0.7% | ||
| Q1 24 | 5.6% | 0.8% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
PCOR
| US | $298.3M | 85% |
| Non Us | $50.9M | 15% |
